Affiliation:
1. Department of Medicinal Chemistry Institute of Chemistry Saint Petersburg State University Saint Petersburg 199034 Russian Federation
2. Center of Bio- and Chemoinformatics I.M. Sechenov First Moscow State Medical University Moscow 119991 Russian Federation
3. Department of Neurofarba Universita degli Studi di Firenze Florence 50019 Italy
4. Immanuel Kant Baltic Federal University Kaliningrad 236041 Russian Federation
Abstract
AbstractA newly introduced diazo reagent, 1‐diazo‐N,N‐bis(4‐methoxybenzyl)methanesulfonamide, enables access to a range of azole‐based primary sulfonamides via [3+2] cycloaddition followed by protecting group removal. Such compounds are representative of the sulfonamide chemical space highly relevant but hitherto not investigated in the context of inhibition of therapeutically relevant isoforms of carbonic anhydrase enzyme. Using this reagent, three sets of primary sulfonamides based on pyrazole, 1,2,3‐triazole and tetrazole cores were synthesized and profiled for inhibition of tumor‐associated hCA IX and XII isoforms as well as abundant cytosolic hCA I and II isoforms. Using virtual library design and docking prioritization tool of the Schrödinger suite, one of the promising leads was evolved into a dual hCA IX/XII inhibitor with excellent selectivity over off‐target hCA I and II. The new synthetic strategy to access azole‐based primary sulfonamides will support the discovery of novel, isoform‐selective inhibitors of carbonic anhydrase within the poorly explored azole chemical space.
Funder
Russian Science Foundation
Subject
Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献